Wells Fargo & Company Increases Zimmer Biomet (NYSE:ZBH) Price Target to $98.00

Zimmer Biomet (NYSE:ZBH) had its target price increased by Wells Fargo & Company from $93.00 to $98.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 5.32% from the company’s previous close.

ZBH has been the topic of several other research reports. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $94.00 to $120.00 in a research note on Monday, January 5th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $100.00 price objective (down from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Sanford C. Bernstein boosted their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Stifel Nicolaus set a $110.00 target price on Zimmer Biomet in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $106.10.

Zimmer Biomet Price Performance

ZBH stock traded up $1.65 during mid-day trading on Wednesday, hitting $93.05. The stock had a trading volume of 272,704 shares, compared to its average volume of 2,292,380. The firm has a fifty day simple moving average of $89.97 and a 200 day simple moving average of $95.64. The firm has a market capitalization of $18.44 billion, a P/E ratio of 23.02, a P/E/G ratio of 2.29 and a beta of 0.62. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. Zimmer Biomet has a 52 week low of $84.59 and a 52 week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The business had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same quarter last year, the business posted $2.31 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current year.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently bought and sold shares of the stock. Key Financial Inc grew its stake in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 163 shares during the period. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Root Financial Partners LLC bought a new stake in Zimmer Biomet in the 3rd quarter worth about $31,000. Cary Street Partners Investment Advisory LLC increased its stake in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 149 shares during the last quarter. Finally, Flagship Harbor Advisors LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $32,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat — EPS $2.42 vs $2.38 est and revenue $2.24B, up 10.9% YoY, driven by strong hip/knee demand; this is the primary bullish catalyst. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Positive Sentiment: Analyst support — BTIG reaffirmed a Buy with a $112 price target (roughly 22% upside vs. current price), which can lend further confidence to buyers. Benzinga BTIG coverage
• Neutral Sentiment: FY‑2026 guidance set to $8.30–$8.45 EPS and revenue $8.4–$8.6B — roughly in line with consensus on EPS but slightly conservative on revenue, so guidance is more measured than bullish. Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance
• Negative Sentiment: Margin contraction noted in the quarter — operating/margin pressure (partly from costs and tariffs) reduces near-term earnings leverage and explains management’s conservative tone. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
• Negative Sentiment: Analyst caution — Needham reaffirmed a Hold, and management flagged tariff and margin headwinds that could limit upside until FCF/margin trends improve. Benzinga Needham coverage

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.